News

Neurology News Network for the week ending July 11, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 10, 2020.

Cure SMA gives an overview of the recent 2020 Virtual SMA Conference, with highlights on new data and poster sessions.

The latest program from Cure SMA aims to better understand the capacity of spinal muscular atrophy centers in the US and to continue to carry out effective clinical trials.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on the feasibility of genotyping, phasing, and targeting of SNPs in Huntington disease.

The FDA has set the Prescription Drug User Fee Act action date for Q4 2020 for the AstraZeneca agent.

In the phase 1/2 study, the Biogen agent showed a favorable reduction of SOD1 concentrations compared to placebo, particularly with the 100-mg dose, and is being assessed in an ongoing phase 3 study, VALOR.

Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.

Reduced amplitude and/or robustness of the rhythms, rather than disrupted timing, are the most indicative of a subsequent risk of PD, independent of nighttime sleep disturbances.

The National Institutes of Health program, dubbed Accelerating Leading-edge Science in ALS, or ALS2, is set to invest $25M over 5 years for exceptionally creative and riskier research.

The associate professor of neurology at Vanderbilt University Medical Center spoke to the findings of a recent study in Huntington disease that assessed the feasibility of selectively knocking down mutant protein expression.

New data suggest that peripapillary retinal nerve fiber layer thinning may be an independent and novel risk factor for conversion to multiple sclerosis in those with RIS.

Biogen’s biologics license application for aducanumab is supported by the phase 3 EMERGE and ENGAGE trials. The company has also requested a priority review designation.

Findings of the study provide a cautionary note in relation to cannabis use in people with MS, at least with respect to depression.

The lack of effect on cognitive function provides reassurance to clinicians and parents for the developmental outcomes of a well-recognized, albeit relatively uncommon, adverse event after immunization.

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.

The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on his and colleagues’ study of single nucleotide polymorphisms in Huntington disease.

One of the first case-series studies that analyzed children with COVID-19 suggest that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.

The dual orexin receptor antagonist improved sleep maintenance and total sleep time without residual next-day effects.

New findings indicate that cognitive health in old age depends in part on cognitive development in early life.

Located in the “Stroke Belt” of the US, Virginia presents a unique perspective on the interplay of social, ethnic, and cultural implications on population health.

In part 1 of this interview, Daniel Ontaneda, MD, PhD, the co-principal of the CAVS-MS study, outlines the reasons for why the central vein sign can lower rates of misdiagnosing multiple sclerosis.

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

Neurology News Network for the week ending July 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

An NIH-funded study provided supporting evidence of an association between high levels of gram-negative bacteria and a stroke-, seizure-, and headache-inducing vascular abnormality.

In the wake of the COVID-19 pandemic, health care providers and patients have had to quickly adapt to new formats of care models to promote safety while retaining care standards.

Fred Cohen, MD, offers insight on his study exploring the utility of combined Botox with anti-CGRP preventives for patients with chronic migraine.